Skip to main content
KTTA
NASDAQ Life Sciences

PAS-004 Cuts Cutaneous Neurofibroma Size 41% in Phase 1/1b, Two Partial Responses in Plexiform Tumors

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.51
Mkt Cap
$17.372M
52W Low
$0.281
52W High
$2.06
52W Position info
81% above low
Off High info
75% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

KTTA sits 81% above its 52-week low of $0.281 on light trading volume (0.3× avg).

Summary

Pasithea reported the first actual efficacy data for oral PAS-004 in NF1 patients: all 15 evaluable participants had reductions in summed target cutaneous neurofibroma surface area, with a median best reduction of 41%. At the 4, 8 and 12mg doses planned for Phase 2, the median best reduction was 46%, and all six patients treated at 4mg and 8mg exceeded 40%. Reductions deepened with time — median 12% at Cycle 1, 38% at Cycle 4 and 49% at Cycle 12 — and the 4mg cohort reached 71% at Cycle 15. In plexiform neurofibromas, all 18 evaluable patients showed tumor volume reductions and two hit the REiNS partial-response threshold at 12mg and 15mg, one at the first on-treatment MRI. Safety was clean: no treatment-related serious adverse events, no discontinuations, and 97.6% of related events were Grade 1 or 2. This follows the September 14 announcement that the data would be presented and the November 3 FDA IND clearance for a randomized Phase 2 cNF trial of roughly 200 patients; the results support the 4-12mg dose range for that study. For a micro-cap clinical-stage name, a positive efficacy readout in a condition with no FDA-approved systemic therapy is the kind of binary event that resets the story. Next catalysts are the Phase 2 trial start and pharmacodynamic analyses of resected cNFs expected in 2027.

At the time of this announcement, KTTA was trading at $0.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.4M. The 52-week trading range was $0.28 to $2.06. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

KTTA - Latest Insights

KTTA
Nov 03, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.3591
Real-time Price: $0.510 info
Change: +$0.1509 (+42%) info
Market Cap: $17.372M info
KTTA
Sep 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.550
Real-time Price: $0.510 info
Change: -$0.040 (-7%) info
Market Cap: $17.372M info
KTTA
Sep 09, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.5697
Real-time Price: $0.510 info
Change: -$0.0597 (-10%) info
Market Cap: $17.372M info
KTTA
Aug 21, 2026, 5:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.490
Real-time Price: $0.510 info
Change: +$0.020 (+4%) info
Market Cap: $17.372M info
KTTA
Jul 29, 2026, 5:15 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.4231
Real-time Price: $0.510 info
Change: +$0.0869 (+21%) info
Market Cap: $17.372M info